Halozyme Therapeutics (HALO) Falls Short of Q4 Views
Tweet
Share
E-mailGet Alerts HALO Hot Sheet
Price: $110.19 -0.51%
EPS Growth %: +30.2%
Financial Fact:
Net income (loss): -28.95M
Today's EPS Names:
VIVO, BIOX, PMCB, More
EPS Growth %: +30.2%
Financial Fact:
Net income (loss): -28.95M
Today's EPS Names:
VIVO, BIOX, PMCB, More
Join SI Premium – FREE
Halozyme Therapeutics, Inc. (Nasdaq: HALO) reported Q4 loss of $0.17, $0.05 worse than the analyst estimate of ($0.12). Revenue for the quarter came in at $3.6 million versus the consensus estimate of $5.33 million.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- H.C. Wainwright Reiterates Buy Rating on Halozyme Therapeutics (HALO)
- Campbell Soup (CPB) Reports In-Line Q4 EPS, Misses on Revenue; Offers FY27 EPS Guidance
- Victoria's Secret & Co. (VSXY) Tops Q2 EPS by 20c ; Offers Guidance
Create E-mail Alert Related Categories
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
